It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Vascular senescence is thought to play a crucial role in an ageing-associated decline of organ functions; however, whether vascular senescence is causally implicated in age-related disease remains unclear. Here we show that endothelial cell (EC) senescence induces metabolic disorders through the senescence-associated secretory phenotype. Senescence-messaging secretomes from senescent ECs induced a senescence-like state and reduced insulin receptor substrate-1 in adipocytes, which thereby impaired insulin signaling. We generated EC-specific progeroid mice that overexpressed the dominant negative form of telomeric repeat-binding factor 2 under the control of the Tie2 promoter. EC-specific progeria impaired systemic metabolic health in mice in association with adipose tissue dysfunction even while consuming normal chow. Notably, shared circulation with EC-specific progeroid mice by parabiosis sufficiently transmitted the metabolic disorders into wild-type recipient mice. Our data provides direct evidence that EC senescence impairs systemic metabolic health, and thus establishes EC senescence as a bona fide risk for age-related metabolic disease.
Vascular senescence is closely associated with individual ageing, while its causative role remains unclear. Here Barinda et al. generate endothelial cell-specific progeroind mice, and reveal that endothelial cell senescence directly induces metabolic disorders through senescence-messaging secretomes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Kobe Pharmaceutical University, Laboratory of Clinical Pharmaceutical Science, Kobe, Japan (GRID:grid.411100.5) (ISNI:0000 0004 0371 6549); Universitas Indonesia, Department of Pharmacology and Therapeutic, Faculty of Medicine, Jakarta, Indonesia (GRID:grid.9581.5) (ISNI:0000000120191471)
2 Kobe Pharmaceutical University, Laboratory of Clinical Pharmaceutical Science, Kobe, Japan (GRID:grid.411100.5) (ISNI:0000 0004 0371 6549)
3 Kobe Pharmaceutical University, Laboratory of Medical Pharmaceutics, Kobe, Japan (GRID:grid.411100.5) (ISNI:0000 0004 0371 6549)
4 Kyoto Prefectural University Graduate School of Medical Science, Department of Cardiology, Kyoto, Japan (GRID:grid.258797.6) (ISNI:0000 0001 0697 4728)
5 Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)
6 Kobe Pharmaceutical University, Laboratory of Clinical Pharmaceutical Science, Kobe, Japan (GRID:grid.411100.5) (ISNI:0000 0004 0371 6549); Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe, Japan (GRID:grid.31432.37) (ISNI:0000 0001 1092 3077)